glp 1 dental side effects If you’re taking a GLP-1 medication like Ozempic or Wegovy, you’re likely familiar with common like nausea. However, a newer concern is gaining traction: "Ozempic Teeth." While it sounds Ozempic Teeth': Another Effect of

Description

You can read the full article at

Maintain your muscle and bone health while working towards your weight loss goals with GLP-1 Support Muscle Guard Protein

Study Population : 1,961 adults without diabetes Average age: 46 years Average baseline BMI: 37.9 Average baseline weight: 231.3 pounds 74.1% female, 25.9% male 76.6% White, 11.6% Black, 7.0% Asian, 4.8% Other Intervention : Semaglutide 2.4 mg subcutaneously once weekly (n=1,306) Placebo subcutaneously once weekly (n=655) Both groups: Individual counseling sessions every 4 weeks promoting 500-calorie deficit and 150 minutes/week physical activity Duration : 68 weeks Primary Outcome - Mean Percentage Weight Loss : Semaglutide: -14.9% (95% CI: -15.3 to -14.5) Placebo: -2.4% (95% CI: -3.0 to -1.8) Difference: -12.4 percentage points (p0.001) Secondary Outcomes - Categorical Weight Loss : 5% weight loss : 86.4% semaglutide vs 31.5% placebo 10% weight loss : 69.1% semaglutide vs 12.0% placebo 15% weight loss : 50.5% semaglutide vs 4.9% placebo 20% weight loss : 32.0% semaglutide vs 1.7% placebo Trial Completion Rates : Semaglutide: 81.7% completed 68 weeks Placebo: 82.0% completed 68 weeks High completion rates suggest good tolerability and participant satisfaction Safety Data : Gastrointestinal adverse events: 74.2% semaglutide vs 47.9% placebo Serious adverse events: 9.8% semaglutide vs 6.4% placebo Discontinuation due to adverse events: 7.0% semaglutide vs 3.1% placebo STEP 2: Diabetes Population Trial Citation : Davies M, et al

It can raise your risk for conditions like type 2 diabetes, heart disease, osteoarthritis, sleep apnea, and cancer

The insulin resistance in PCOS might also occur independently of body weight, due to inherited post-receptor defects in insulin signalling that affects metabolism and mitotic pathways, not only in classic insulin target tissues, such as skeletal muscle, liver, and adipose tissue, but also in the non-classical target tissues, such as pituitary and ovary [12, 16]